For General Information, page-2786

First 2786 Last

Share
Profile

Follow
Jakolu

141 Posts.

42

12/09/23

16:36

Post #: 69829360
Share

Originally posted by George1972: ↑

@chilunsun
I have looked into the tea leaves and the ball tickler we may experience is thus forth:

Going on what has been repeatedly and consistently said by management … Charmaine, Anthony and James all; at various times.

1) a deal is not contingent on Tox data

2) ANP not taking this drug to market

3) ANP only have enough funds to complete the trial

4) they are now also talking about selling the drug in markets like Japan and China!! This is significant!!

5) they constantly refer to the Capricor deal with NS Pharma for the US only being US$30m upfront, US$700m+ in milestones and royalties.

6) NS pharma only have 1 exon skipping drug approved in the US.

7) They consistently say Capricor’s drug is not as efficacious as ATL1102 and therefore would not have anywhere the potential revenue as ATL1102

8) James stated in the share café presentation last Friday .. “a licensing deal could come NEXT MONTH, NEXT QUARTER or NEXT YEAR “ !!!!! Next month??? This is a new one. Maybe it is contingent on a new deal with Ionis??

9) they repeatedly say that ATL1102 will be the Standard of Care for DMD and all other drugs will piggy back on ours in combination. This is a powerful statement.

On this basis, I will take a wild stab and say there will be a licensing deal before Xmas. It will be for the US only. It will be US$30m to US$50m upfront. With US$500m on FDA approval and then double digit (17% to 22% licensing fee).

It may also come with the licensor paying for a US based P2b exon skipping combination trial which would cost them US$20m. There would also be another milestone payment on a successful Combo trial result.

ANP retain worldwide rights Ex USA.

So in conclusion
US$30m to US$50m cash
US$500m milestone late 2024 on FDA
20% royalties
Potential milestones on successful combo trial

ANP retain rest of world rights for
DMD
ANP retains LMGD
ANP retain PRV
The other thing I considered was maybe the Licensor may take a 10% equity stake in ANP as well like Roche did with Sarepta. They would pay extra cash for that and get a board seat.

Thoughts?

Expand

Brilliant writeup George! Based on your 'back of the napkin' calcs, what type of market cap do you foresee with that scenario?

ANP Price at posting: 6.8¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

PL3

Patagonia looks to raise $2.15M for South American exploration and development

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

There are more pages in this discussion • 741 more messages in this thread...

First 2786 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.6¢		Change 0.001(1.18%)		Mkt cap ! $77.53M

Open	High	Low	Value	Volume
8.5¢	8.8¢	8.4¢	$18.63K	218.7K

Buyers (Bids)

No.	Vol.	Price($)
1	30000	8.5¢

Sellers (Offers)

Price($)	Vol.	No.
8.6¢	46681	1

View Market Depth

No.	Vol.	Price($)
1	30000	0.085
1	29206	0.083
2	96888	0.082
1	38100	0.081
4	217800	0.080

Price($)	Vol.	No.
0.086	46681	1
0.088	96794	4
0.089	135000	2
0.090	443317	5
0.091	108000	1

Last trade - 16.10pm 09/07/2024 (20 minute delay)

PER (ASX) Chart

For General Information, page-2786

Patagonia looks to raise $2.15M for South American exploration and development

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

For General Information, page-2786

Top Stories

Patagonia looks to raise $2.15M for South American exploration and development

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News